论文部分内容阅读
目的观察依那普利联合益水生新饮治疗高血压肾损害患者的临床疗效。方法选择我院高血压肾损害患者90例,随机分组分为观察组和对照组,每组各45例,对照组给予依那普利治疗,观察组在对照组基础上联合中药方剂益水生新饮治疗,观察两组治疗效果。结果观察组治疗后,总有效率为95.56%,对照组总有效率为80.0%,两组比较差异有统计学意义(P<0.05);观察组治疗后尿α1微球蛋白(24.06±4.36)mg/L,血肌酐(70.66±9.37)μmol/L,尿素氮(5.16±0.72)mmol/L;对照组治疗后尿α1微球蛋白(33.68±6.89)mg/L,血肌酐(81.37±13.51)μmol/L,尿素氮(5.84±1.19)mmol/L,组间对比差异有统计学意义(P<0.05)。结论采用依那普利联合益水生新饮治疗高血压肾损害疗效可靠,能够明显改善患者肾脏功能指标,值得在临床上推广使用。
Objective To observe the clinical efficacy of enalapril in combination with Yisheng Sheng Yin in patients with hypertensive renal impairment. Methods 90 cases of hypertensive renal damage in our hospital were randomly divided into observation group and control group, 45 cases in each group, the control group was enalapril treatment, the observation group on the basis of the control group, Drink treatment, observe the treatment effect of two groups. Results After treatment, the total effective rate was 95.56% in the observation group and 80.0% in the control group. The difference between the two groups was statistically significant (P <0.05). Urinary α1 microglobulin (24.06 ± 4.36) (33.68 ± 6.89) mg / L, serum creatinine (81.37 ± 13.51 mg / L, serum creatinine 70.66 ± 9.37 μmol / L and urea nitrogen 5.16 ± 0.72 mmol / ) μmol / L and urea nitrogen (5.84 ± 1.19) mmol / L, respectively. There was significant difference between the two groups (P <0.05). Conclusion Enalapril and Yisheng Shengyin can treat hypertension nephropathy reliably. It can significantly improve the renal function of patients and is worth popularizing in clinic.